Health Canada has made two announcements aimed at modernizing and streamlining submissions for biologic drugs, for both biosimilars and innovative biologic drugs. Stakeholders are encouraged to provide comments on the draft guidance to Health Canada until September 8, 2025.
In November 2024, Health Canada published amendments to the Food and Drug Regulations, including a new Division 4 directed specifically to biologic drugs2. Health Canada introduced the new Division 4 Regulations (the new Regulations) to replace those originally dating back to the 1950s and 1960s, which Health Canada viewed as outdated, overly prescriptive and unnecessarily product-specific. Health Canada has stated that the new Regulations are intended to provide a flexible, outcome-based approach to the regulation of biologic drugs, including a modern approach to identifying submission requirements. The new Regulations came into force on July 1, 2025.
Despite the fact that Division 4 has been completely replaced, new guidance published by Health Canada clarifies that these new Regulations will not result in significant changes to submission requirements at this time. Health Canada’s new guidance is intended to help manufacturers with the transition of regulatory requirements under the old Division 4 Regulations to the new Division 4 Regulations, and to explain how the requirements of the old regulations track onto the new regulatory language.
Although the regulatory language has been updated to be less prescriptive, Health Canada has stressed that current practices will not be changing at this time. Rather, the new Regulations are designed to enshrine Health Canada’s current approach to biologic drug oversight in a modern regulatory framework. For example, previously Health Canada would occasionally require periodic quality reporting for certain drugs, which was applied using a discretionary and risk-based approach. This practice is now enshrined in the new Regulations, and specifically allows for increased flexibility in the ability of Health Canada to require periodic quality reporting and to prescribe any terms of that reporting.
Health Canada has also moved to modernize and streamline submission requirements for biosimilar drugs. Consistent with current Health Canada practice, the proposed submission requirements for biosimilar drugs are not set out in new regulations, but instead are found in a new proposed industry guidance document. Several changes have been proposed, and Health Canada has opened a consultation for stakeholders and other interested parties to submit comments until September 8, 2025.
Some of the proposed major changes to biosimilar submission requirements include:
These proposed changes to the guidance reflect Health Canada statements in recent years which downplay the importance of clinical studies in supporting biosimilar applications. For instance, in a 2023 webinar hosted by the U.S. Food and Drug Administration (FDA), a Health Canada spokesperson emphasized that the requirement for comparative clinical efficacy studies could be waived if certain pharmacodynamic information is available, and that at the time, nine biosimilar drugs had been approved in Canada without clinical efficacy trial data3. The proposed changes appear to enshrine this approach as the new Canadian default.
It also appears that Health Canada’s changes to its biosimilar guidance mirror similar developments by the FDA (which has proposed guidance updates eliminating the need for biosimilar manufacturers to provide clinical switching studies)4 and the European Medicines Agency (which has published a new guidance document providing a pathway for biosimilars to be approved without comparative efficacy studies)5. Health Canada typically tries to move in step with its peer regulators where it feels that such regulatory changes would not compromise the health and safety of Canadians, and it appears such an approach is being taken with the draft biosimilar guidance it has published for consultation.
Stakeholders are encouraged to provide comments on the draft guidance to Health Canada until September 8, 2025. The timeline for finalized guidelines is unknown at this stage.
To discuss these issues, please contact the author(s).
This publication is a general discussion of certain legal and related developments and should not be relied upon as legal advice. If you require legal advice, we would be pleased to discuss the issues in this publication with you, in the context of your particular circumstances.
For permission to republish this or any other publication, contact Janelle Weed.
© 2025 by Torys LLP.
All rights reserved.